The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Share News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,436.00
Bid: 1,436.00
Ask: 1,438.00
Change: 8.00 (0.56%)
Spread: 2.00 (0.139%)
Open: 1,426.00
High: 1,443.00
Low: 1,420.00
Prev. Close: 1,428.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Indivior appoints Mark Crossley as CEO

Mon, 29th Jun 2020 07:44

(Sharecast News) - Indivior has promoted Mark Crossley to the role of chief executive officer, succeeding Shaun Thaxter.
Crossley, who has been chief financial and operations officer at Indivior since February 2017, was chief strategy officer from 2014 to 2017 and served as finance director, leading the demerger of Indivior from its former parent.

Prior to joining the company in 2012, he spent 13 years at Procter & Gamble in various finance leadership positions and eight years as an officer in the United States Coast Guard.

Shaun Thaxter is stepping down stepping down by mutual agreement with the board.

Meanwhile, Ryan Preblick, currently senior vice president of Global Financial Planning and Analysis Commercial Operations, has been appointed interim CFO.

Indivior, which makes opioid addiction treatment product Suboxone Film, said it will initiate a search for a permanent CFO and will assess whether to appoint a separate operations officer.

Crossley said: "There remains a very significant opportunity for Indivior in the years ahead, and I look forward to working with the board to deliver the full potential of our key assets, to resolve outstanding investigations and litigations as expeditiously as possible, and to ensure that we continue to play a leading role in helping patients, doctors, and communities fight the human crisis of opioid addiction."

More News
30 Jun 2021 17:05

LONDON MARKET CLOSE: Lower finish fails to dent FTSE's strong quarter

LONDON MARKET CLOSE: Lower finish fails to dent FTSE's strong quarter

Read more
30 Jun 2021 13:44

Wednesday broker round-up

(Sharecast News) - Workspace: RBC Capital Markets upgrades to outperform with a target price of 1,050p.

Read more
30 Jun 2021 12:17

LONDON MARKET MIDDAY: Stocks slide ahead of US ADP jobs report

LONDON MARKET MIDDAY: Stocks slide ahead of US ADP jobs report

Read more
30 Jun 2021 10:41

Indivior raises profit and revenue guidance after strong start to year

Indivior raises profit and revenue guidance after strong start to year

Read more
30 Jun 2021 09:02

LONDON MARKET OPEN: Indivior shines after upgrading guidance

LONDON MARKET OPEN: Indivior shines after upgrading guidance

Read more
30 Jun 2021 07:58

LONDON MARKET PRE-OPEN: Dividend contrast from Dixons and Stagecoach

LONDON MARKET PRE-OPEN: Dividend contrast from Dixons and Stagecoach

Read more
30 Jun 2021 07:35

Indivior lifts 2021 guidance after better-than-expected H1

(Sharecast News) - Opioid addiction treatment maker Indivior lifted its 2021 guidance on Wednesday following a better-than-expected business performance through the first half of the year.

Read more
21 Jun 2021 09:34

BROKER RATINGS: UBS cuts Rio Tinto to Sell; Morgan Stanley ups Ocado

BROKER RATINGS: UBS cuts Rio Tinto to Sell; Morgan Stanley ups Ocado

Read more
8 Jun 2021 14:27

IN BRIEF: Indivior secures license for cannabis disorder treatment

IN BRIEF: Indivior secures license for cannabis disorder treatment

Read more
8 Jun 2021 12:36

Indivior joins forces with France's Aelis on treatment for cannabis use disorder

(Sharecast News) - Indivior said on Tuesday that it has teamed up with French biotechnology group Aelis to advance the clinical development of a treatment for cannabis use disorder.

Read more
8 Jun 2021 12:36

Indivior teams up with Aelis on treatment for cannabis use disorder

(Sharecast News) - Indivior said on Tuesday that it has teamed up with French biotechnology group Aelis to advance the clinical development of a treatment for cannabis use disorder.

Read more
6 May 2021 17:50

UPDATE: Pay comes under spotlight at BAE, Indivior and Rio Tinto AGMs

UPDATE: Pay comes under spotlight at BAE, Indivior and Rio Tinto AGMs

Read more
29 Apr 2021 16:11

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
29 Apr 2021 12:26

Indivior maintains 2021 guidance as first quarter revenue increases

Indivior maintains 2021 guidance as first quarter revenue increases

Read more
28 Apr 2021 10:47

Indivior says US filings "administrative", no new Suboxone settlements

Indivior says US filings "administrative", no new Suboxone settlements

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.